| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NA | Ruxolitinib | Jakafi | 10 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| J2502 | Pasireotide | Signifor, Signifor LAR | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 2012 | Jan 1, 2016 | In Use | |||
| J1447 | Tbo-filgrastim | Granix | 1 mcg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2015 | Jan 1, 2016 | In Use | ||
| J9274 | Tebentafusp-tebn | Kimmtrak | 1mcg | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | No | 2022 | Sep 27, 2022 | In Use | ||
| C9095 | Tebentafusp-tebn | Kimmtrak | 1mcg | Immunotherapy | T Cell Receptor (TCR) | HLA-A*02:01 | No | 2022 | Mar 25, 2022 | Sep 27, 2022 | No Longer Used | |
| J9380 | Teclistamab cqyv | Tecvayli | 0.5mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2022 | Jul 11, 2023 | In Use | ||
| NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Ruxolitinib | Jakafi | 20 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Sotorasib | Lumakras | Multiple | Chemotherapy | RAS Inhibitor | KRASG12C | Yes | 2021 | In Use | |||
| C9293 | Glucarpidase | Voraxaze | 10 units | Ancillary Therapy | Chemoprotective | Antidote | No | 2012 | Jan 1, 2012 | In Use | ||
| J9249 | Melphalan (Apotex) | Melphalan (Apotex) | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2017 | Apr 17, 2024 | In Use | ||
| J1446 | Tbo-filgrastim | Granix | 5 mcg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2015 | Jan 1, 2016 | Dec 31, 2015 | No Longer Used | |
| J9317 | Sacituzumab govitecan-hziy | Trodelvy | 2.5mg | Immunotherapy | Drug Antibody Conjugate | Trop-2 | No | 2020 | Jan 1, 2021 | In Use | ||
| C9148 | Teclistamab-cqyv | Tecvayli | 0.5mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2022 | Mar 17, 2023 | Jul 11, 2023 | No Longer Used | |
| NA | Panobinostat | Farydak | 15 mg | Chemotherapy | Enzyme Inhibitor | HDAC | Yes | 2015 | In Use | |||
| C9454 | Pasireotide | Signifor, Signifor LAR | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 2012 | Jan 1, 2016 | In Use | |||
| J2505 | Pegfilgrastim | Neulasta:Neulasta Onpro | 6 mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2002 | Jan 1, 2004 | Jan 26, 2022 | No Longer Used | |
| C1086 | Temozolomide | Temodar | 5 mg | Chemotherapy | Alkylating Agent | Tetrazine | Yes | 1999 | Jan 1, 2010 | In Use | ||
| J9326 | Telisotuzumab vedotin-tllv | Emrelis | 1mg | Immunotherapy | Drug Antibody Conjugate | c-MET | No | 2025 | Jan 12, 2026 | In Use | ||
| J9390 | Vinorelbine | Navelbine | 10 mg | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | No | 1994 | Jan 1, 1996 | In Use | ||
| C9440 | Vinorelbine | Navelbine | 10 mg | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | No | 1994 | Jan 1, 2005 | Dec 31, 2005 | No Longer Used | |
| NA | Thalidomide | Thalomid | 200 mg | Immunotherapy | Immunomodulator | Thalidomide Analog | Yes | 1998 | In Use | |||
| NA | lenvatinib | Lenvima | 4 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT,RET | Yes | 2015 | In Use | |||
| C9475 | Necitumumab | Portrazza | 1 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2015 | Apr 1, 2016 | In Use | ||
| NA | Nintedanib | Ofev | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, FLT3 | Yes | 2014 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home